The global exosome diagnostic and therapeutic market size was estimated at $224.34 million in 2020, and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030.
The global exosome diagnostic and therapeutic market size was estimated at $224.34 million in 2020, and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030.
Exosome is the membrane-bound vesicle that is synthesized in the extracellular compartment of the eukaryotic cells. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Biomolecules, including proteins, metabolites, and nucleic acids are delivered by exosomes into target cells effectively to alter their biological response. Exosomes are engineered to deliver diverse therapeutic payloads, including short interfering ribonucleic acid (RNAs), antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. Exosome vesicle-based liquid biopsy is used for potential utilization in diagnosis and determining the prognosis of patients with cancer and other diseases.
Full Report is Ready | Request Sample of This Report @ https://qyresearchmedical.com/sample/112590
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global exosome diagnostic and therapeutic market. The COVID-19 pandemic has stressed healthcare systems in the world and increased the need for advanced hospitals. Implementation of the spread of COVID-19 infection increased the need for molecular diagnosis and drive the growth of the market.
The exosome diagnostic and therapeutic market share is primarily driven by increase in prevalence of chronic disease, infectious disease, autoimmune disease and cancer and surge in demand for molecular diagnosis. In addition, ongoing advance exosome technology in drug development and discovery yields valuable information regarding the heterogeneity and biological function and enhances the ability to harness the therapeutic and diagnostic potential for cancer & infectious disease. Thus, advancement in technology in healthcare sector propels the growth of the exosome diagnostic market, and exosome therapeutic market.
Scope of the Report
| Report Coverage | Details |
| Market Size in 2020 | USD 224.34 Million |
| Revenue Forecast by 2030 | USD 2.9 Billion |
| Base Year | 2021 |
| Forecast Data | 2022 to 2030 |
Increase in demand for drug therapies and surge in R&D activities in pharmaceutical and biopharmaceutical field which is stimulated by the potential of exosome technologies as diagnostic and therapeutic tools are used for the treatment of various diseases, including neurodegeneration, cardiovascular dysfunction, and cancer. Increase in potential application of exosome in cancer diagnosis and development of translational precision medicine increase the use of exosome diagnostic and therapeutic industry and surge the growth of exosome diagnostic market, and exosome therapeutic market.
The key factor for the exosome diagnostic and therapeutic market growth includes increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer disease , Parkinson’s disease , and cancer, including breast, prostate, liver, and lung cancer which , in turn, boosts to growth of the market . Furthermore, on August 2020, Aethlon Medical, a healthcare company, announced the collaboration with University of Pittsburgh on National Institute of Health Grant for treatment of head and neck cancer. Exosomes are nanosized particles that are released in large quantities from cancer cells and carry complement of a tumor’s genetic and protein cargo, which fuel cancer growth and immune suppression.
In addition, in April 2020, Exosome Diagnostics, a biotechnology company, announced the launch of ExoDx Prostate test kit at-home. ExoDx Prostate (EPI) test is a urine-based, genomic test that helps to detect prostate cancer . This liquid biopsy test recently received coverage in the VA Healthcare system through a General Services Administration (GSA) award and is included in the National Cancer Comprehensive Network (NCCN) guidelines for early detection in men .
Exosomes Diagnostic And Therapeutic Market Segmentation
The exosome diagnostic and therapeutic market is segmented into application, product, end user and region. Depending on the application, it is divided into diagnostic and therapeutic applications. By the product, it is fragmented into instrument, reagents, and software. According to end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations).
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
By application, the diagnostic segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for early diagnosis. However, the therapeutics segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for drug development.
Depending on product, the reagents segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. However, the instrument segment is expected to witness considerable growth during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in number of key manufacturer.
According to end user, the cancer institute segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of cancer, increase in number of hospitals and surge in initiatives by government for development of healthcare infrastructure. However, the diagnostic center segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for molecular diagnosis.
Region wise, North America garnered a major share in the exosome diagnostic and therapeutic market in 2020, and is expected to be dominant during the exosome diagnostic and therapeutic market forecast period, owing to rise in prevalence of chronic disorder, increase in number of product launch for exosome therapeutics, surge in presence of key players, and development of R&D activities in pharmaceutical and biopharmaceutical sector in the region. However, Asia-Pacific is expected to register highest CAGR of 30.3% from 2021 to 2030, owing to increase in prevalence of chronic and infectious disorder, growth in health care expenditures, rise in number of exosome diagnostic and therapeutic industry and surge in demand for molecular diagnosis.
The key players operating in the global exosome diagnostic and therapeutic market include Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark). The other players in the value chain include 101BIO, AMS Biotechnology Limited, Therapeutic Solutions International, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, ExoCyte Therapeutics Pte Ltd., Cell Guidance Systems LLC, BioRegenerative Sciences, Inc., Evomic Science LLC, and NorgenBiotek Corp.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
- By Application
- Diagnostic
- Therapeutic
- By Product
- Instrument
- Reagent
- Software
- By End User
- Cancer Institute
- Hospital
- Diagnostic Center
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- North America
Key Market Players
- Aethlon Medical, Inc.
- Exosome Diagnostic, Inc.
- NanoSomix, Inc
- Thermo Fisher Scientific, Inc.
- Malvern Instruments Ltd
- System Biosciences, Inc
- NX Pharmagen
- Sistemic Ltd
- Capricor Therapeutics, Inc.
- Exiqon A/S
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/112590/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/